When was Immunic founded?

Immunic was founded in 2003 and raised its 1st funding round 13 years after it was founded.

Where is Immunic located?

Immunic is headquartered in New York City, United States. It is registered at New York, New York.

How many employees does Immunic have?

As of Jul 31, 2026, the latest employee count at Immunic is 94.

Is Immunic a funded company?

Immunic is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Sep 27, 2016.

When was the latest funding round of Immunic?

Immunic's latest funding was a $***** Post IPO round on Feb 13, 2026, with participation from 11 investors.

Where does Immunic rank among its competitors?

Immunic ranks 79th amongst 413 active competitors, of which 140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immunic, which secured $400M in Feb, 2026.

Who are the top competitors of Immunic?

Immunic's top competitors include Biogen, Abcellera Biologics and Sana Biotechnology. Among them, Immunic secured the most recent funding round in February, 2026.

Immunic - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases. The product pipeline of the company includes vidofludimus calcium (IMU-838), a selective immune modulator for multiple sclerosis, IMU-935, a selective inverse agonist targeted for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome and IMU-856, for bowel barrier dysfunction.

Website: imux.com
Social
Email ID: *****@imux.com
Phone Number: +1 **********
Registered Address: New York, New York

Key Metrics

Founded Year

2003

Location

New York City, United States

Stage

Public

Latest Funding Round

Post IPO, Feb 13, 2026, $*****

Investors

Janus Henderson Investors & 22 more

Ranked

79^th among 413 active competitors

Employee Count

94 as on Jul 31, 2026

Similar Companies

Biogen & 483 more

Exit Details

Public

View Immunic's full profile

Immunic is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
IMMUNIC, INC. CIN: 562358443 , United States, Active	Dec 31, 1999	-	7 (As on Dec 31, 2024)	-
Immunic, Inc CIN: 56-2358443 , United States, Active	Dec 31, 2002	-	77 (As on Dec 31, 2023)	-
IMMUNIC, INC. CIN: 5660722 , United States, Active	Nov 22, 2019	-	-	-
Immunic Ag CIN: HRB223333 , Germany, Active	Jan 24, 2016	-	28 (As on Mar 31, 2021)

Immunic got listed on Apr 17, 2014.

Click here to take a look at Immunic's IPO in detail

Immunic has raised funding over 4 rounds. Its first funding round was on Sep 27, 2016. Its latest funding round was a Post IPO round on Feb 13, 2026 for $*****. 11 investors participated in its latest round. Immunic has 23 institutional investors.

Here is the list of recent funding rounds of Immunic:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 13, 2026	7527909	Post IPO	6727571	7934315	8109345	4058262
Jan 04, 2024	6798194	Post IPO	9955074	5774053	6827163	6094906
Oct 10, 2022	5418572	Post IPO	2355051	4178386	1122809	2450326

Access funding benchmarks and valuations. Sign up today!

View details of Immunic's funding rounds and investors

Immunic's employee count trend

Immunic has 94 employees as of Jul 26. Here is Immunic's employee count trend over the years:

Uncover Immunic's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Immunic include Biogen, Abcellera Biologics and Sana Biotechnology. Here is the list of Top 10 competitors of Immunic, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
2nd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	74/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
6th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Fidelity Investments & 13 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
8th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	Woodford Investment Management, General Atlantic ... & 50 others	69/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Apax & 16 others	68/100
79th	Immunic 2003, New York City (United States), Public	Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases	-	Janus Henderson Investors, BVF Partners & 21 others	54/100